Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst • 16 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib
ALPINE ASCEND

Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data so far for acalabrutinib and zanubrutinib, novel BTK inhibitors for chronic lympocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Barbara Eichhorst

The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Barbara Eichhorst • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Barbara Eichhorst • 7 Dec 2025
Final analysis of GAIA/CLL13: second-line treatment in CLL after venetoclax-based frontline
1:42
Final analysis of GAIA/CLL13: second-line treatment in CLL after venetoclax-based frontline
Barbara Eichhorst • 7 Dec 2025
Two-year follow-up results from EPCORE CLL-1: epcoritamab monotherapy in Richter's transformation
1:29
Two-year follow-up results from EPCORE CLL-1: epcoritamab monotherapy in Richter's transformation
Barbara Eichhorst • 7 Dec 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Barbara Eichhorst • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Barbara Eichhorst • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Barbara Eichhorst • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Barbara Eichhorst • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals